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Abstract
Background & aims
Serum interferon-gamma-inducible protein-10 (IP-10) is elevated in cholestatic liver dis-
eases and predicts response to antiviral therapy in patients with chronic hepatitis C virus
(HCV) infection. Dipeptidylpeptidase 4 (DPPIV) cleaves active IP-10 into an inactive form,
which inhibits recruitment of CXCR3+ T cells to the liver. In this study the link between IP-10
levels, DPPIV activity in serum and CXCR3+ T cells is analysed in cholestatic and non-cho-
lestatic liver patients.
Methods
In serum DPPIV activity (by enzymatic assay), IP-10 (by ELISA) and bile acids (BA) (by
enzymatic assay) were analysed in 229 naive HCV genotype (GT) 1 patients and in 16
patients with cholestatic liver disease. In a prospective follow-up (FU) cohort of 27 HCV GT
1 patients peripheral CD3+CXCR3+, CD4+CXCR3+ and CD8+CXCR3+ cells were mea-
sured by FACS.
Results
In 229 HCV patients serum IP-10 levels correlated positively to DPPIV serum activity.
Higher IP-10 levels and DPPIV activity were detected in cholestatic and in cirrhotic HCV
patients. Increased IP-10 serum levels were associated with therapeutic non-response to
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antiviral treatment with pegylated-interferon and ribavirin. In the HCV FU cohort elevated IP-
10 serum levels and increased BA were associated with higher frequencies of peripheral
CD3+CXCR3+, CD4+CXCR3+ and CD8+CXCR3+ T cells. Positive correlation between
serum IP-10 levels and DPPIV activity was likewise validated in patients with cholestatic
liver diseases.
Conclusions
A strong correlation between elevated serum levels of IP-10 and DPPIV activity was seen in
different cholestatic patient groups. Furthermore, in cholestatic HCV patients a functional
link to increased numbers of peripheral CXCR3+ immune cells could be observed. The
source of DPPIV release in cholestatic patients remains open.
Introduction
Cholestasis is characterized by elevated hepatic and serum bile acids (BA) and may lead to
changes in liver tissue such as acute hepatocellular toxicity, bile duct proliferation and fibrosis
progression up to biliary cirrhosis [1]. High serum BA levels are a hallmark in cholestatic liver
diseases with obstructive jaundice and likewise in primarily noncholestatic liver diseases such
as chronic hepatitis C virus (HCV) infection [2, 3]. In HCV patients, increased BA serum lev-
els have been previously associated with a non-response to former antiviral treatment with
pegylated interferon (Peg-IFN) and ribavirin (RBV) and were proposed as predictors for the
severity of liver fibrosis [3–5]. We recently described an association between genetic predispo-
sition for cholestasis with a polymorphism in the gene coding for the bile salt export pump
(BSEP; ABCB 11 1331C allele) and non-sustained virological response (SVR) in a HCV patient
cohort [6]. In the same work patients with non-achieving SVR had significantly higher serum
BA levels than those with SVR. Furthermore, increased BA levels are associated to direct acting
antiviral treatment with ombitasvir/paritaprevir/ritonavir ± dasabuvir in a recent preliminary
study of 20 HCV patients probably due to alterations of bile acid transport [7].
Higher expression of the chemokine interferon γ inducible protein 10 (IP-10/CXCL10) in
liver and peripheral blood is described in patients with chronic HCV infection and are associ-
ated with liver fibrosis [8, 9]. In HCV patients pretreatment levels of IP-10 are a good predic-
tive marker for therapy outcome and correlate to non-response to antiviral treatment [10–13].
Additionally, changes of serum IP-10 in HCV patients treated with sofosbuvir and ribavirin
mirrored HCV RNA and seemed to be an indicator of innate immune viral recognition [14].
T cell migration into the liver is conducted by chemokine production in liver tissue, e.g. IP-
10 and monokine induced by interferon-gamma (MIG/ CXCL9). Both chemokines are prefer-
entially expressed by sinusoidal epithelium and recruit T cells into the liver by binding to
CXCR3, a receptor that is upregulated on activated lymphocytes [12]. Thus, IP-10 is an impor-
tant chemokine for selective immune cell trafficking to the liver by binding to CXCR3 [8]. The
NH2-terminal region of chemokines is crucial for receptor binding and signaling activities and
the activity of chemokines can be regulated by post-translational modification [15]. N-termi-
nal removal of two amino acids of active IP-10 (aIP-10) by dipeptidyl peptidase 4 (DPPIV/
CD26) leads to an antagonist form (cIP-10) [15, 16]. In the study of Casrouge et al. the antago-
nist form of IP-10 (cleaved IP-10 (cIP-10)) was elevated in HCV patients especially in patients
with non-response to antiviral treatment. [16]. The antagonist form of IP-10 (c-IP10) still
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binds to CXCR3 receptor but without induction of signaling and therefore without recruit-
ment of immune cells into the liver. The authors concluded that the dominant form of IP-10
in HCV patients is the antagonist form and this chemokine antagonism may contribute to
treatment failure due to an impaired immune cell recruitment into the liver [16]. In conse-
quence, a higher abundance of these immune cells remains detectable in the peripheral blood.
Furthermore, a recent study demonstrated that the truncation of IP-10 alters lymphocyte
migration and limits infiltration of tumor parenchyma in mice and can be reversed through
the DPPIV inhibitor sitagliptin [17]. It is challenging to study post-transcriptional modifica-
tions of chemokines in biological samples, as it is difficult to monitor the different protein
forms.
The serine protease DPPIV is present on different cell types, e.g. the canalicular membrane
of hepatocytes, the apical membrane of cholangiocytes, and lymphocytes. Elevated serum
activity is described in patients with cholestatic liver disease such as biliary atresia, primary bil-
iary cirrhosis, in HCV patients as well as in animal models with bile duct ligation [18–20].
From the above described data, we hypothesized that high serum BA favors release of
DPPIV and subsequently an increase in serum levels of IP-10 (cIP-10), which leads to a
reduced infiltration of CXCR3 positive cells into the liver. Finally, these events could account
for the unfavorable effect of reduced viral clearance in HCV patients, but also have clinical
impact on infectious complications in other cholestatic liver diseases.
The aim of this study was to analyse IP-10 serum levels as well as DPPIV activity in
cholestatic HCV patients. The influence of IP-10 levels and DPPIV activity on circulating
immune cells was investigated in a smaller follow-up cohort of HCV infected patients. Find-
ings were furthermore validated in 16 cholestatic patients with other underlying cholestatic
liver diseases.
Methods
Patient cohorts
Hepatitis C patients. 229 patients with HCV GT 1 infection were included in this study
after written informed consent. 48 patients from the Swiss Hepatitis C Cohort Study (SCCS)
and 181 patients from the Berlin cohort were recruited between 2000 and 2008. The study was
approved by the local ethics committees (University Hospital Zu¨rich EK-695; Berlin cohort
AZ205/2002). Response to antiviral treatment with Peg-IFN and RBV was documented by
SVR and Non-SVR including relapse, partial response and non-response to antiviral treat-
ment. Serum samples were collected before antiviral treatment and stored immediately at
-80˚C.
Hepatitis C follow-up (FU) cohort and healthy controls. Serum samples and peripheral
blood mononuclear cells (PBMC) were collected in 27 HCV GT 1 patients and 17 healthy con-
trols (HC) after approval by the local ethics committees (University Hospital Wu¨rzburg AZ53/
12) and given written informed consent. HCV patients in this cohort were either treatment-
naive or showed relapse to a previous antiviral treatment. HC had no evidence of any liver dis-
ease by medical history and questionnaire.
Cholestatic non-HCV validation cohort. Six patients with primary biliary cirrhosis
(PBC), six patients with primary sclerosing cholangitis (PSC) and 4 patients with bile duct
drainage were included in this study after written informed consent and approval by local eth-
ics committees (University Hospital Erlangen AZ238_13B) Serum BA were measured before
(mean = 114 ± 104 μM) and after treatment with cholestyramine in PBC/PSC patients for 2 to
3 weeks (mean = 90 ± 140 μM). Serum samples of patients with biliary drainage were available
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at day 0 and at day 3 after bile duct drainage (Table 1). 3 out of 4 patients had decrease in
serum BA, whereas 1 patient had increase in serum BA on day 3.
IP-10 measurement
Quantitative determination of human IP-10 (overall IP-10, no differentiation of aIP-10 or cIP-
10) in serum was carried out using the HK311 human IP-10 ELISA KIT (Hycult biotech, PA).
Measurable concentration range is from 20 to 5,000 pg/mL. Serum samples were diluted (1:4)
as described in the protocol and the absorbance was measured at 450 nm.
IP-10 levels in serum samples of the FU cohort (27 patients with chronic HCV infection
and 17 HC) were measured as overall IP-10, aIP-10 and c-IP10 by diagnostic lab, Myriad-
Rules Based Medicine (Austin, USA). In 18 patients overall IP-10 was under the lower limit
of quantification of this assay. These patients were included in the analysis with the value
of the lower limit of quantification (212 pg/mL). In the cholestatic non-HCV validation
cohort (n = 16) IP-10 serum concentration was measured by using the Human CXCL10/IP-
10 Quantikine ELISA kit (R&D Systems, Minneapolis, USA) measuring overall IP-10 (no
differentiation of aIP-10 or cIP-10). The ELISA was performed according to the manufactur-
er’s instructions.
Serum DPPIV activity
Enzymatic activity of DPPIV was measured in serum by a chromogenic substrate (H-Gly-Pro-
pNA) (Enzo Life science, Farmingdale, NY). Cleavage of the p-nitroaniline (pNA) from the
chromogenic substrate increases absorbance at 405 nm.
Flow cytometry of PBMC
100 μl of peripheral patient blood were incubated with 10 μl of antibody (CD3 PC5 Beckman
Coulter (Beckman Coulter, Brea, CA), CD4 ECD Beckman Coulter and CXCR3 Alexa Fluor
488 Biolegend (Biolegend, San Diego, CA) and thereafter VersaLyse (Beckman Coulter, Brea,
CA) was added. After standard washing procedure stained cells were analysed and measured
by flow cytometry.
Table 1. Patient characteristics.
Patient characteristics % (n)
Hepatitis C patients n = 229
sex m/f 62.4 (143) / 37.6 (86)
cirrhosis/non-cirrhosis/missing 16.6 (38)/ 74.7 (171)/ 8.7 (20)
SVR/no SVR 34.5 (79)/ 65.5(150)
BA elevated/non-elevated 40.6 (93)/ 59.4 (136)
Hepatitis C follow-up cohort n = 27
sex m/f 59.3 (16) / 40.7 (11)
cirrhosis/non-cirrhosis 22.2 (6)/ 77.8 (21)
treatment-naiv/no SVR 63.0 (17)/ 37.0 (10)
BA elevated/non-elevated 11.1(3)/ 88.9 (24)
Cholestatic non-HCV patients n = 16
sex m/f 31.3 (5)/68.9 (11)
PSC/PBC/biliary drainage 37.5 (6)/ 37.5 (6)/ 25 (4)
https://doi.org/10.1371/journal.pone.0208225.t001
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Bile acid measurement
Serum BA levels in 256 patients were analysed as described previously [21]. 100 μl of serum
were diluted by 100 μl isotonice saline, BA measurement was performed enzymatically with
spectrophotometric detection (Trinity Biotech, Wicklow, Ireland). The upper reference
limit was 8 μM. Serum BA levels were considered elevated above 10μM, as this this cut-off is
considered clinically relevant for the risk assessment to predict complications in intrahepatic
cholestasis of pregnancy. Total serum BA levels in the cohort of 16 cholestatic patients were
quantified using Diazyme total bile salts kit (Diazyme Laboratories, Poway, CA) according to
the manufacturer’s instructions.
Statistical analysis
Statistical analyses were performed using SPSS (19.0, SPSS Inc., Chicago) and graphs were cre-
ated with Prism5 (GraphPad Software, La Jolla, CA).
The independent, unpaired t-test or the non-parametric Wilcoxon-Mann-Whitney-test
(group with n� 10 or missing normal distribution) was used as appropriate to analyse differ-
ences between groups. Correlation was calculated by using Spearman-Rho or Pearson-Rho in
non-parametric or normal distributed variables as appropriated. A P-value less than 0.05 were
considered statistically significant (�), p< 0.01 = (��), p< 0.001 = (��).
Results
Serum IP-10 and DPPIV activity are correlated to cholestasis and cirrhosis
in HCV patients
IP-10, BA levels and DPPIV activity in serum were analysed in a cohort of 229 naive HCV-
patients. Detailed patient characteristics are depicted in Table 1.
Cholestasis was defined as elevated serum BA concentration > 10μM. The cut-off level of
10μM was chosen as this cut- off is considered clinically relevant for the risk assessment to pre-
dict complications in intrahepatic cholestasis of pregnancy [22]. 93 of 229 patients (40.6%) had
elevated serum BA before antiviral treatment (Table 1) and these patients showed also signifi-
cantly higher IP-10 serum levels compared to patients without cholestasis (Fig 1A). IP-10 is
undergoing a post-translational modification with a N-terminal cleavage by DPPIV leading to a
truncated form (antagonist form of IP-10 (cIP-10)) that binds to CXCR3 receptor, but does not
induce cellular signalling and thereby leads to a 10-fold reduced chemotactic potency [15]. In
our large cohort of HCV patients, DPPIV serum activity and serum IP-10 levels (no differentia-
tion between aIP-10 and cIP-10) showed a positive correlation (Pearson-rho 0.25 (p<0.001)
(Fig 1B). Interestingly, cholestatic HCV patients (serum BA concentration > 10 μM) had a sig-
nificantly higher enzymatic activity of DPPIV in serum compared to non-cholestatic HCV
patients (Fig 1C).
Furthermore, higher IP-10 serum levels were associated with impaired therapy response in
this cohort of HCV patients. Patients with non-SVR had significantly higher serum IP-10 lev-
els before treatment as compared to patients with SVR (Fig 1D). In line with this finding non-
SVR patients had also significantly higher DPPIV serum activity as well as a trend towards ele-
vated serum BA in comparison to HC (Fig 1E and 1F).
In cirrhotic patients (n = 38) significant higher serum BA (mean ± SEM: 25.2 ± 3.4 μM)
were observed compared to non-cirrhotic patients (n = 171) (10.8 ± 1.1 μM, p< 0.001). These
patients with advanced disease showed also significantly higher IP-10 serum levels as well as
DPPIV serum activity as depicted in Fig 2A–2C.
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Peripheral CXCR3+ T cells are linked to higher serum IP-10 in cholestatic
HCV patients
In a prospective follow-up (FU) cohort of 27 HCV GT 1 patients and 17 HC PBMC were ana-
lysed together with above described serum markers to investigate the mechanistic relationship
between serum IP-10 levels and CXCR3+ T cells. Clinical characteristics are depicted in
Fig 1. Serum IP-10 levels, DPPIV activity and BA levels in HCV patients (n = 229). A) Cholestatic HCV patients with serum
BA> 10μM had higher IP-10 serum levels. Mean ± SD (Wilcoxon Mann Whitney test; �� = p<0.01). B) Positive correlation
between IP-10 serum levels and DPPIV serum activity (Pearson-Rho 0.25; p<0.01). C) Cholestatic HCV patients had higher DPPIV
serum activity. Mean ± SD (Wilcoxon Mann Whitney test; ��� = p<0.001). D) Non-SVR patients had higher IP-10 levels (E),
higher DPPIV serum activity (F) and a trend towards higher serum BA compared to HC. Mean ± SD (Wilcoxon Mann Whitney
test; �� = p< 0.01).
https://doi.org/10.1371/journal.pone.0208225.g001
Fig 2. HCV patients with cirrhosis. HCV patients with cirrhosis (n = 38) had significantly higher IP-10 and BA serum levels as well
as DPPIV serum activity compared to patients without cirrhosis. Total HCV cohort n = 229. Mean ± SD. � = p< 0.05; �� = p< 0.01;
��� = p< 0.001 (Wilcoxon Mann Whitney test).
https://doi.org/10.1371/journal.pone.0208225.g002
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Table 1. Serum IP-10 and BA concentrations were significantly higher in HCV patients com-
pared to HC. DPPIV serum activity showed no significant difference between HCV patients
and HC (Fig 3A–3C).
The chemokine IP-10 binds to CXCR3, a receptor that is expressed on activated lymphocytes.
In this FU cohort peripheral CD3+CXCR3+, CD4+CXCR3+ and CD8+CXCR3+ cells were ana-
lysed. HCV patients had significantly more CD3+CXCR3+, CD4+CXCR3+ and CD8+CXCR3+
cells compared to HC (HCV vs. healthy controls; mean ± SEM CD3+CXCR3+: 50.6 ± 1.8
vs. 30.5 ± 1.6%, CD4+CXCR3+: 48.7 ± 1.9 vs. 32.1 ± 2.3% and CD8+CXCR3+: 63.7 ± 2.4 vs.
42.6 ± 2.3%) (Fig 4A–4C). Furthermore, a positive correlation was observed for IP-10 serum lev-
els and CD3+CXCR3+ (Spearman-Rho 0.62; p<0.001), CD4+CXCR3+ (Spearman-Rho 0.64;
p<0.001) and CD8+CXCR3+ T cells (Spearman-Rho 0.47; p<0.01) (Fig 4D–4F).
In this small FU cohort, the above described analyses in the large cohort were repeated and
are depicted in S1 Fig. Only three patients were cholestatic in the FU cohort. These patients
had higher IP-10 serum levels, but no significant difference was observed in DPPIV serum
activity compared to individuals without cholestasis. Cirrhotic patients (n = 6) had signifi-
cantly higher IP-10 serum levels as well as BA levels compared to non-cirrhotic patients. For
DPPIV serum activity no significant difference between cirrhotic and non-cirrhotic patients
was observed in this small cohort. Further BA differentiation has been performed by gas chro-
matography-mass spectrometry HPLC-MS/MS. Taurine-conjugated BA were significantly ele-
vated an associated to higher IP-10 serum levels in HCV patients (S2 Fig).
In this FU cohort serum IP-10 levels were analysed by diagnostic lab (Myriad RBM) to
differentiate cIP-10 from agonist IP-10 (aIP-10). But aIP-10 was only detected in two HCV
patients and cIP-10 only in three patients and four HC. Therefore, no in-depth analysis could
be performed with these data (data not shown).
Immune cell changes were also analysed in cholestatic as well as in cirrhotic patients in the
FU cohort. Three cholestatic patients showed a trend towards higher CD3+CXCR3+ T cells
in peripheral blood and six cirrhotic patients had a trend towards higher frequency of CD4
+CXCR3+ T cells (S3 Fig). One could speculate that due to the low number of cholestatic and
cirrhotic patients these results did not reach significance.
Cholestatic non-HCV patients showed as validation cohort a strong
interplay between serum IP-10 levels and DPPIV serum activity
In this patient group PBC, PSC as well as patients with biliary drainage were included. Six
patients with PBC and six patients with PSC received treatment with cholestyramine against
Fig 3. Serum IP-10, BA and DPPIV activity in a prospective FU cohort. 27 HCV patients IP-10 levels as well as BA levels were
significantly higher compared to HC. DPPIV serum activity was higher in HCV patients, but without reaching statistically
significance. Mean ± SD. (Wilcoxon Mann Whitney test) ��� = p< 0.001; � = p< 0.05.
https://doi.org/10.1371/journal.pone.0208225.g003
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pruritus for 2–3 weeks. Eight patients had a decrease in serum BA during cholestyramine
treatment (relative change mean ± SD: -51.5 ± 22.7%) and four patients had an increase
in serum BA (relative change: +86.1 ± 47.0%). Three of four patients with biliary drainage
had a decrease in serum BA and one patient showed increased serum BA on day three after
drainage.
In this validation cohort a positive correlation between relative changes in DPPIV serum
activity and IP-10 levels over time was observed (Rho pearson 0.468, p< 0.05). Cholestatic
patients with relative increase in IP-10 serum levels over time had significantly more often an
increase in relative changes of DPPIV serum activity (Fig 5A). Seven representative patients
with the highest decrease of serum BA over time are depicted in Fig 5B. No homogenous trend
towards decrease in IP-10 serum levels and DPPIV activity before and after treatment with
cholestyramine or biliary drainage was observed.
Discussion
Cholestasis with elevated serum BA is a hallmark in chronic liver disease. In the present study
serum markers such as IP-10 and DPPIV activity were analysed in cholestatic HCV patients to
investigate a possible linkage between IP-10, DPPIV and cholestasis. Higher IP-10 serum levels
can be observed in different liver pathologies, e.g. viral hepatitis B/C, PBC, biliary atresia and
autoimmune liver disease with normalisation after treatment response [10, 11, 13, 23–25]. In
our large cohort of 229 HCV patients higher IP-10 serum levels were observed in cholestatic
HCV patients as well as in patients with therapeutic non-response to antiviral treatment and
Fig 4. Immmunological data of FU cohort with 27 HCV patients and 17 HC. HCV patients had higher frequency of (A)
CD3+CXCR3+, (B) CD4+CXCR3+ and (C) CD8+CXCR3+ T cells in peripheral blood. Mean ± SD. (Wilcoxon Mann Whitney test)
��� = p< 0.001; �� = p< 0.01; � = p< 0.05. D-F) Correlation between serum IP-10 levels and peripheral (D) CD3+CXCR3+, (E)
CD4+CXCR3+ and (F) CD8+CXCR3+ T cells. Spearman Rho as indicated.
https://doi.org/10.1371/journal.pone.0208225.g004
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IP-10 serum levels were correlated to higher serum DPPIV activity (Fig 1). But in the above-
mentioned studies no information about serum BA as hallmark of progressive liver disease has
been reported. In our study analysis of serum BA was performed and a significant association
between higher IP-10 serum levels and higher serum BA was described for the first time in
cholestatic HCV patients (Fig 1).
Casrouge et al. first described higher levels of IP-10 antagonist form (cIP-10) after cleavage
by DPPIV in 34 patients with chronic HCV infection. Higher levels were measured in treat-
ment non-responders as compared with responders. Furthermore in 5 patients initiating anti-
viral treatment with PEG-IFN and RBV, decreased number of CXCR3 expressing cells were
detected in the circulation 6 hours after first dosage together with higher IP-10 serum levels
[16]. In our FU study analyses of CD3+CXCR3+, CD4+CXCR3+ and CD8+CXCR3+ cells
were performed and a significant higher frequency of CXCR3 expressing T cells was detected
in patients with chronic HCV infection (n = 27) (Fig 4A–4C). Furthermore, higher IP-10
serum levels were correlated to higher frequency of CD3+CXCR3+, CD4+CXCR3+ and CD8
+CXCR3+ cells (Fig 4D and 4E). These correlations indicate the disturbed homing of CXCR3
+ T cells in HCV patients by post-transitional modified IP-10. In line with our hypothesis, that
cholestasis could lead to a higher DPPIV serum activity and therefore higher antagonist form
of IP-10 (cIP-10), three HCV patients with increased serum BA showed a trend toward higher
frequency of CD3+CXCR3+ T cells in peripheral blood. Due to the low patient number no sta-
tistical significance was reached (S3 Fig).
It is challenging to study post-transcriptional modifications of chemokines (such as aIP-10
and cIP-10) in biological samples, as it is difficult to monitor the different protein forms [26].
In a cohort of 69 Egyptian patients with chronic HCV GT 4 infection IP-10 agonist (aIP-10)
and antagonist (cIP-10) forms were analysed, but the antagonist form (cIP-10) was not
detected with the exception of three patients [27]. In our prospective FU cohort, the same
assay was performed but the antagonist (cIP-10) form was not detected with the exception of
three patients and four HC (data not shown) In recent studies a novel ultrasensitive single-
molecule assay (Simoa) was used to distinguish aIP-10 and cIP-10 [26, 28]. One of these stud-
ies analysed the effects of DPPIV inhibition in healthy controls and HCV patients. The treat-
ment with 100mg sitagliptin preserved the bioactive form of IP-10 (aIP-10) [26]. In a recent
study Blauenfeldt et al. analysed the homing effect of CXCR3+ T cells by IP-10 in patients with
tuberculosis. In this study, patients with active tuberculosis had high levels of cIP-10 and a
reduced frequency of CXCR3+ T cells was observed at the pulmonal site of infection compared
Fig 5. Validation cohort with cholestatic liver disease (PBC/PSC) and biliary drainage (n = 16). A) Patients with relative
decrease/increase in IP-10 had significantly relative decrease/increase in DPPIV serum activity. B-C) Seven representative patients
with highest decrease in BA and the corresponding (B) serum IP-10 and (C) DPPIV activity over time.
https://doi.org/10.1371/journal.pone.0208225.g005
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to peripheral blood. This finding reflects a possible regulatory role of DPPIV in homing of
CXCR3+ T cells to the site of infection [29]. This finding is in line with our hypothesis, that
cIP-10 (antagonist form) leads to an inefficient homing of CXCR3+ T cells at the site of infec-
tion (e.g. lung for tuberculosis or in the present study liver for HCV infection).
The origin of DPPIV is still not properly understood. However, there are different studies
suggesting the hepatobiliary system as primary source because of a strong correlation between
liver enzymes and DPPIV serum levels in patients with different liver pathologies (e.g. viral
hepatitis, non-alcoholic fatty liver disease, hepatocellular carcinoma and cirrhosis) [30, 31].
DPPIV was also proposed as a serum marker for cholestasis since good correlation to serum
bilirubin was described [20]. But in these studies, no measurement of serum BA as hallmark
of chronic liver disease was performed. Activated T cells and especially Th17 cells show high
expression of CD26/DPPIV and could likewise be source of higher DPPIV activity [32].
To underline our findings independently of HCV infection DPPIV serum activity, IP-10
serum levels and serum BA were quantified in a cohort of cholestatic patients with PSC, PBC
or biliary drainage. Similar, in this non-HCV cohort DPPIV serum activity correlated with IP-
10 serum levels (Fig 5A). However, no strong correlation between serum IP-10/DDPIV and
BA was observed in this non-viral validation cohort (Fig 5B). This could be explained by low
patient numbers of these rare disease entities and heterogeneous cholestatic liver pathologies
in this cohort. To further analyse the origin of observed increase in DPPIV serum activity in
vitro experiments on cholangiocytes were performed (data not shown). But no difference on
DPPIV mRNA expression was observed 8h after stimulation with TLC, CDCA, INT-747 and
TGR5 agonist. Therefore, further in vitro studies with different cell lines (hepatocytes, immune
cells) are needed to better understand the observed increase in DPPIV activity.
In summary, there is a strong linkage between increased levels of serum BA, IP-10 and
DPPIV activity in HCV patients. In cholestatic HCV patients these changes had impact on
peripheral immune cells with higher frequency of CXCR3+ T cells. In cirrhotic patients BA,
IP-10 serum levels as well as DPPIV activity was higher and cirrhotic patients showed a trend
towards higher frequency of peripheral CD3+CXCR3+ T cells. These observations could be
expression of the advance liver pathology and characterize cirrhotic patients as difficult to
treat patients with increase susceptibility for infections.
The above described results underline our initial hypothesis that elevated serum BA could
contribute to higher DPPIV activity, but the underlying mechanism remains elusive. Since
these observations are of clinical importance for the basic understanding of cholestasis with
immune modulatory capacity of BA and hepatic inflammation in various liver diseases, further
analysis of the underlying mechanism of the described associations is warranted. The question
of whether BA per se or other mediators retained during cholestasis are causative for increased
DPPIV activity remains open and deserves further in vitro investigation.
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Mann Whitney test; � = p<0.05. C-E) IP-10 serum levels, DPPIV serum activity and BA in
cirrhotic patients and patients without cirrhosis. Mean ± SD. Wilcoxon Mann Whitney test;
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